PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients

NCT00174356 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: CI 1033
DRUG: PACLITAXEL
DRUG: CARBOPLATIN

Sponsor

Pfizer